Financial Statements · From SEC 10-K & 10-Q XBRL Filings
Boston Scientific Corporation Revenue & Financial Statements
Boston Scientific Corporation reported revenue of $20.1B for the fiscal year ended December 31, 2025, up 19.9% year over year, with net income of $2.9B and diluted EPS of $1.94.
- Company
- Boston Scientific Corporation BSX · NYSE
- Latest fiscal year
- FY ended Dec 31, 2025
- Statements
- Income · Balance Sheet · Cash Flow — 5 fiscal years, 8 quarters
Income Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 11.9B | 12.7B | 14.2B | 16.7B | 20.1B |
| Cost of revenue | 3.7B | 4.0B | 4.3B | 5.3B | 6.2B |
| Gross profit | 8.2B | 8.7B | 9.9B | 11.5B | 13.9B |
| Operating income | 1.2B | 1.6B | 2.3B | 2.6B | 3.6B |
| Pretax income | 1.7B | 2.3B | 2.4B | 2.5B | 3.7B |
| Net income | 1.0B | 698.0M | 1.4B | 2.1B | 2.9B |
| Diluted EPS | 0.69 | 0.45 | 1.07 | 1.25 | 1.94 |
| EBITDA | 2.3B | 2.8B | 3.5B | 3.9B | 5.0B |
Quarterly
| USD | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.9B | 4.1B | 4.2B | 4.6B | 4.7B | 5.1B | 5.1B | 5.3B |
| Cost of revenue | 1.2B | 1.3B | 1.3B | 1.5B | 1.5B | 1.6B | 1.5B | 1.6B |
| Gross profit | 2.6B | 2.9B | 2.9B | 3.1B | 3.2B | 3.4B | 3.5B | 3.7B |
| Operating income | 675.0M | 520.0M | 733.0M | 675.0M | 921.0M | 819.0M | 1.0B | 825.0M |
| Pretax income | 608.0M | 420.0M | 669.0M | 585.0M | 805.0M | 941.0M | 939.0M | 700.0M |
| Net income | 578.0M | 356.0M | 177.0M | 969.0M | 372.0M | 103.0M | 788.0M | 670.0M |
| Diluted EPS | 0.33 | 0.22 | 0.32 | 0.38 | 0.45 | 0.53 | 0.51 | 0.45 |
| EBITDA | 979.0M | 618.0M | 1.0B | 1.0B | 1.2B | 930.0M | 1.4B | 1.2B |
Balance Sheet
Fiscal year-end snapshots. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total assets | 32.2B | 32.5B | 35.1B | 39.4B | 43.7B |
| Current assets | 6.3B | 5.8B | 6.5B | 6.9B | 8.8B |
| Cash & equivalents | 1.9B | 928.0M | 865.0M | 414.0M | 2.0B |
| Total liabilities | — | — | — | — | — |
| Current liabilities | 4.3B | 3.8B | 4.9B | 6.4B | 5.4B |
| Long-term debt | — | — | — | — | — |
| Total debt | — | — | — | — | — |
| Stockholders’ equity | — | — | 19.3B | 21.8B | 24.2B |
| Net debt | — | — | — | — | — |
Cash Flow Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | 1.9B | 1.5B | 2.5B | 3.4B | 4.5B |
| Investing cash flow | (1.6B) | (2.0B) | (2.6B) | (5.7B) | (2.6B) |
| Financing cash flow | (95.0M) | (548.0M) | 5.0M | 1.8B | (395.0M) |
| Capital expenditure | 554.0M | 588.0M | 711.0M | 790.0M | 876.0M |
| Free cash flow | 1.3B | 938.0M | 1.8B | 2.6B | 3.7B |
| Dividends paid | 55.0M | 55.0M | 28.0M | 0 | — |
| Stock-based compensation | 194.0M | 220.0M | 233.0M | 266.0M | 299.0M |
Figures are parsed from SEC XBRL company facts and may be derived where issuers report year-to-date values (quarterly figures differenced; Q4 computed as FY minus Q3). Fiscal periods follow each company's fiscal calendar, not calendar years. Historical fact, not investment advice — verify with official SEC filings.
Every BSX filing, connected
Financials beside price, insider trades, and 8-K events — with alerts the moment something new is filed.